JP2008538812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538812A5 JP2008538812A5 JP2008506405A JP2008506405A JP2008538812A5 JP 2008538812 A5 JP2008538812 A5 JP 2008538812A5 JP 2008506405 A JP2008506405 A JP 2008506405A JP 2008506405 A JP2008506405 A JP 2008506405A JP 2008538812 A5 JP2008538812 A5 JP 2008538812A5
- Authority
- JP
- Japan
- Prior art keywords
- bound
- sdldl
- amount
- particles
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002245 particle Substances 0.000 claims 20
- 238000000034 method Methods 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 210000004369 blood Anatomy 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 4
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 4
- 102100029470 Apolipoprotein E Human genes 0.000 claims 4
- 101710095339 Apolipoprotein E Proteins 0.000 claims 4
- 102000006410 Apoproteins Human genes 0.000 claims 4
- 108010083590 Apoproteins Proteins 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 102000007592 Apolipoproteins Human genes 0.000 claims 3
- 108010071619 Apolipoproteins Proteins 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 3
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 claims 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 2
- 238000002298 density-gradient ultracentrifugation Methods 0.000 claims 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims 2
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0500808 | 2005-04-11 | ||
| PCT/SE2006/000425 WO2006110082A1 (en) | 2005-04-11 | 2006-04-10 | A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538812A JP2008538812A (ja) | 2008-11-06 |
| JP2008538812A5 true JP2008538812A5 (enExample) | 2009-04-09 |
Family
ID=37087285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008506405A Withdrawn JP2008538812A (ja) | 2005-04-11 | 2006-04-10 | 方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090280501A1 (enExample) |
| EP (1) | EP1872138A1 (enExample) |
| JP (1) | JP2008538812A (enExample) |
| CN (1) | CN101166981A (enExample) |
| WO (1) | WO2006110082A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1756756A (zh) * | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| JP5081814B2 (ja) * | 2006-05-01 | 2012-11-28 | デンカ生研株式会社 | 家族性複合型高脂血症の検出方法 |
| JP2008116248A (ja) * | 2006-11-01 | 2008-05-22 | Yoshikimi Kikuchi | 子宮体癌の検出方法 |
| AT505727B1 (de) * | 2007-09-04 | 2009-06-15 | Univ Innsbruck | Verfahren zur diagnose des metabolischen syndroms |
| EP2344890B1 (en) | 2008-10-20 | 2021-08-11 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods |
| JP2010190804A (ja) * | 2009-02-19 | 2010-09-02 | Biomarker Science:Kk | 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法 |
| US20110008901A1 (en) * | 2009-07-07 | 2011-01-13 | Kiernan Urban A | Apolipoprotein ciii in pre- and type 2 diabetes |
| EP3151012B1 (en) * | 2010-09-21 | 2018-03-21 | Proteomics International Pty Ltd | Biomarkers associated with diabetic nephropathy |
| CN102565416A (zh) * | 2010-12-27 | 2012-07-11 | 中国科学院上海生命科学研究院 | 载脂蛋白a1作为糖尿病标志物的应用 |
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| KR101355394B1 (ko) | 2011-08-03 | 2014-01-29 | 서울대학교산학협력단 | 임신성 당뇨 조기 진단 정보를 제공하는 방법 및 임신성 당뇨 조기 진단 정보를 제공하는데 사용되는 임신성 당뇨 모니터링, 진단 및 스크리닝용 키트 |
| CN103308670B (zh) * | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103376323A (zh) * | 2012-04-25 | 2013-10-30 | 中国科学院上海生命科学研究院 | 载脂蛋白c-iii作为肥胖型糖尿病标志物的应用 |
| CN107884467A (zh) * | 2017-10-31 | 2018-04-06 | 北京毅新博创生物科技有限公司 | 改善质谱检测糖基结晶的方法及产品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030165503A1 (en) * | 2000-03-03 | 2003-09-04 | Jean-Charles Fruchart | Vaccine for the treatment of atherosclerosis |
| WO2002098919A2 (en) * | 2001-06-05 | 2002-12-12 | Genfit | Method for apo ciii measurement in apob and non apob containing particles |
| JP4593026B2 (ja) * | 2001-07-18 | 2010-12-08 | 栄研化学株式会社 | ＳｍａｌｌｄｅｎｓｅＬＤＬの測定方法 |
| WO2003029829A1 (en) * | 2001-10-01 | 2003-04-10 | The Texas A & M University System | Lipoprotein fingerprinting method |
| KR101079386B1 (ko) * | 2002-12-06 | 2011-11-02 | 덴카 세이켄 가부시키가이샤 | 소립자 저비중 리포단백질의 정량 방법 |
-
2006
- 2006-04-10 CN CNA2006800144529A patent/CN101166981A/zh active Pending
- 2006-04-10 EP EP06733281A patent/EP1872138A1/en not_active Withdrawn
- 2006-04-10 JP JP2008506405A patent/JP2008538812A/ja not_active Withdrawn
- 2006-04-10 WO PCT/SE2006/000425 patent/WO2006110082A1/en not_active Ceased
- 2006-04-10 US US11/911,118 patent/US20090280501A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schütte et al. | Markers for predicting severity and progression of acute pancreatitis | |
| Ryu et al. | Pentraxin 3: a novel and independent prognostic marker in ischemic stroke | |
| Daniels et al. | Plasma neutrophil gelatinase–associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study | |
| JP2008538812A5 (enExample) | ||
| Guo et al. | Association between microalbuminuria and cardiovascular disease in type 2 diabetes mellitus of the Beijing Han nationality | |
| CN103403549B (zh) | 败血症的预后的预测方法 | |
| Kolesova et al. | Intriguing findings of liver fibrosis following COVID-19 | |
| Berezin et al. | Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation | |
| Cai et al. | Biomarkers of oxidation stress, inflammation, necrosis and apoptosis are associated with hepatitis B-related acute-on-chronic liver failure | |
| US20130084276A1 (en) | Biomarkers of cardiovascular disease including lrg | |
| JP5415520B2 (ja) | 最大酸素消費量低下の予測のためのプロ−エンドセリン−１ | |
| Al-Saffar et al. | Microalbuminuria in non-diabetic patients with unstable angina/non ST-segment elevation myocardial infarction | |
| Peng et al. | Levels of B-type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus | |
| RU2019106326A (ru) | Гистоны и/или proadm в качестве маркеров, свидетельствующих об органной дисфункции | |
| Karayiğit et al. | Systemic immune-inflammation index (SII) may be an effective indicator in predicting the left ventricular hypertrophy for patients diagnosed with hypertension | |
| Zhao et al. | Prognosis implication of N-terminal pro-B-type natriuretic peptide in adult patients with acute myocarditis | |
| Hsu et al. | Lymphocyte-to-monocyte ratio predicts mortality in cirrhotic patients with septic shock | |
| Ma et al. | High mean platelet volume is associated with worse outcomes in patients with HBV-related decompensated cirrhosis | |
| Liang et al. | Clinical utility of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 concentrations in the assessment of liver fibrosis due to chronic hepatitis B | |
| Jin et al. | 2D shear wave elastography combined with MELD improved prognostic accuracy in patients with acute-on-chronic hepatitis B liver failure | |
| CA2814702A1 (en) | Body fluid bin1 as a marker of cardiac health | |
| Onodera et al. | Plasma B-type natriuretic peptide is useful for cardiovascular risk assessment in community-based diabetes subjects comparison with Albuminuria | |
| CN107589260A (zh) | 尿液中mmp-7作为肾脏纤维化和慢性肾脏病的生物标志物的用途 | |
| JP2025029071A (ja) | 無症候性脳梗塞及び認知低下の評価のためのｉｇｆｂｐ７ | |
| Choi et al. | The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients |